BGLC Providing H/S Measured MoveBGLC being a pharma stock can be unpredictable. Though in the micro, seems to have found a floor and curving for a reversal. Head & Shoulder pattern providing target move fitting fib move to .236.
−0.1608USD
−2.63 MUSD
9.77 MUSD
7.07 M
About BioNexus Gene Lab Corp
Sector
CEO
Lee Su-Leng Tan
Website
Headquarters
Kuala Lumpur
Employees (FY)
18
Founded
2017
FIGI
BBG00N70PLY0
BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.
BGLC gathering momentum to gain some profit .....BGLC gathering momentum to gain some profit though it may be temporary or rather say a correction pattern as we will follow.
we can expect impulsive wave to reach 3.87$ or ABC correction wave.
the sure thing is, after correction comes impulsive so we can see the BGLC rise in the near future.
3.87
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of BGLC is 0.5935 USD — it has increased by 0.15% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange BioNexus Gene Lab Corp stocks are traded under the ticker BGLC.
BGLC stock is 6.06% volatile and has beta coefficient of 0.81. Check out the list of the most volatile stocks — is BioNexus Gene Lab Corp there?
Yes, you can track BioNexus Gene Lab Corp financials in yearly and quarterly reports right on TradingView.
BGLC stock has fallen by 12.72% compared to the previous week, the month change is a 13.48% fall, over the last year BioNexus Gene Lab Corp has showed a 84.93% decrease.
BGLC net income for the last quarter is 308.46 K USD, while the quarter before that showed −2.61 M USD of net income which accounts for 111.82% change. Track more BioNexus Gene Lab Corp financial stats to get the full picture.
Today BioNexus Gene Lab Corp has the market capitalization of 10.56 M, it has decreased by 1.59% over the last week.
No, BGLC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BGLC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BioNexus Gene Lab Corp stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 28, 2024, the company has 18.00 employees. See our rating of the largest employees — is BioNexus Gene Lab Corp on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BioNexus Gene Lab Corp technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BioNexus Gene Lab Corp stock shows the sell signal. See more of BioNexus Gene Lab Corp technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BioNexus Gene Lab Corp EBITDA is −2.99 M USD, and current EBITDA margin is −30.41%. See more stats in BioNexus Gene Lab Corp financial statements.